KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Opko Health (OPK) EBITDA (2016 - 2026)

Opko Health filings provide 17 years of EBITDA readings, the most recent being -$51.0 million for Q1 2026.

  • On a quarterly basis, EBITDA rose 24.05% to -$51.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$34.5 million, a 87.09% increase, with the full-year FY2025 number at -$50.7 million, up 66.66% from a year prior.
  • EBITDA hit -$51.0 million in Q1 2026 for Opko Health, down from $28.4 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $48.1 million in Q3 2025 to a low of -$87.8 million in Q3 2022.
  • Median EBITDA over the past 5 years was -$60.8 million (2024), compared with a mean of -$42.8 million.
  • Biggest five-year swings in EBITDA: tumbled 977.86% in 2024 and later surged 171.55% in 2025.
  • Opko Health's EBITDA stood at -$55.3 million in 2022, then dropped by 24.93% to -$69.0 million in 2023, then increased by 2.72% to -$67.2 million in 2024, then surged by 142.28% to $28.4 million in 2025, then plummeted by 279.64% to -$51.0 million in 2026.
  • The last three reported values for EBITDA were -$51.0 million (Q1 2026), $28.4 million (Q4 2025), and $48.1 million (Q3 2025) per Business Quant data.